Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
4
80%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (80.0%)
Phase 21 (20.0%)

Trials by Status

completed360%
terminated240%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_2

Study of ASN51 in Adults With Early Alzheimer's Disease

NCT06677203
completedphase_1

PET Study of Repeated ASN51 in Healthy Volunteers

NCT05725005
completedphase_1

Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51

NCT06390098
completedphase_1

Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects

NCT06232109
terminatedphase_1

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease

NCT04759365

Clinical Trials (5)

Showing 5 of 5 trials
NCT06677203Phase 2

Study of ASN51 in Adults With Early Alzheimer's Disease

Terminated
NCT05725005Phase 1

PET Study of Repeated ASN51 in Healthy Volunteers

Completed
NCT06390098Phase 1

Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51

Completed
NCT06232109Phase 1

Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects

Completed
NCT04759365Phase 1

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5